Aimmune Archives

Markets Sep. 1, 2020, 3:01 AM

Aimmune Therapeutics soars 172% after Nestle agrees to acquire the peanut allergy treatment company for $2.6 billion

Aimmune Therapeutics soared 172% on Monday after Nestle Health Science agreed to acquire the company for $US34.50 per share, or $US2.6 billion. Aimmune developed a treatment for peanut allergies, Palforzia, which was approved by the FDA in January of this year. But the COVID-19 pandemic derailed Aimmune’s Palforzia launch plans, […]

News Dec. 10, 2018, 1:30 AM

A treatment for the most common food allergy could be available next year, and one biotech just drew ahead in the race for the $3 billion market

2019 could be the year of the first treatment for kids with peanut allergies. Two companies could compete for a market of around $US3 billion – though one, DBV Technologies, just hit a major roadblock The treatments aren’t a cure, but do reduce the risk of a dangerous allergic reaction […]

News Nov. 20, 2018, 7:18 AM

A pill to treat peanut allergies is getting closer to reality — but a new study shows the drug can have some harsh side effects

Researchers are working on new medications to treat allergies by targeting the body’s immune system. According to data published Sunday in the New England Journal of Medicine, biotech company Aimmune found that after a year on its a peanut allergy treatment, 67% of kids with high peanut allergies were able […]

News Feb. 21, 2018, 1:32 AM

An experimental treatment for peanut allergies just succeeded in a key trial

Researchers are working on new medications to treat allergies by targeting the body’s immune system. Biotech company Aimmune found that after a year on its a peanut allergy treatment, 67% of the kids with high peanut allergies were able to tolerate 600 milligrams of peanut protein (about two to four […]